What is the appropriate management for a newly diagnosed osteoporosis in a 65-year-old woman?

Management of Newly Diagnosed Osteoporosis in a 65-Year-Old Woman

For a 65-year-old woman with newly diagnosed osteoporosis, initiate treatment with an oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly) as first-line therapy, combined with calcium and vitamin D supplementation, unless she has very high fracture risk features that would warrant anabolic therapy. 1

Risk Stratification First

Before selecting treatment, determine if she has very high fracture risk, defined as:

• Recent fracture within the past 12 months
• Multiple prior clinical osteoporotic fractures
• Hip or vertebral fracture history
• T-score ≤ -3.0
• Age >74 years with T-score ≤ -2.5
• Failure of previous osteoporosis therapy 2

Treatment Algorithm

For Standard/High Risk (Most 65-Year-Old Women)

Start with oral bisphosphonates as they have proven broad-spectrum antifracture efficacy (spine, hip, and nonvertebral fractures) 1:

• Alendronate 70 mg weekly OR Risedronate 35 mg weekly
• Must be taken after overnight fast, with full glass of water
• Remain upright for 30 minutes after ingestion
• Wait 30 minutes before other medications, food, or beverages 1

Alternative if oral bisphosphonates contraindicated:

• Zoledronate 5 mg IV annually - particularly useful if GI intolerance, esophageal disease, or medication adherence concerns 1
• Denosumab 60 mg subcutaneous every 6 months - no renal dose adjustment needed, but requires transition to bisphosphonate when discontinued to prevent rebound fractures 1

For Very High Fracture Risk

Consider anabolic therapy first, followed by bisphosphonate:

• Romosozumab (sclerostin inhibitor) for 12 months, then transition to bisphosphonate 2
• Teriparatide (recombinant PTH) for up to 24 months, then transition to bisphosphonate 2

The 2023 ACP guideline provides moderate-certainty evidence for romosozumab and low-certainty evidence for teriparatide in reducing fractures in very high-risk postmenopausal women (mean age >74 years) 2. The AACE/ACE 2020 guideline supports anabolic therapy as initial treatment for very high-risk patients, noting that romosozumab showed superior vertebral and clinical fracture reduction compared to alendronate 1.

Essential Non-Pharmacologic Interventions

Calcium and Vitamin D

• Calcium: 1,200 mg daily total intake (diet plus supplement if needed)
• Vitamin D: 800-1,000 IU daily (minimum 400 IU per Health Canada) 3
• Check and correct vitamin D deficiency before starting treatment

Exercise (Twice Weekly Minimum)

• Balance training
• Functional exercises
• Resistance training 3

Fall Prevention

• Home safety assessment
• Vision correction
• Medication review (sedatives, antihypertensives)
• Assistive devices if needed

Lifestyle Modifications

• Smoking cessation
• Limit alcohol to ≤2 drinks daily
• Maintain healthy body weight

Critical Pitfalls to Avoid

Bisphosphonate contraindications:

• Active esophageal disease or stricture
• Inability to remain upright 30 minutes
• Hypocalcemia (must correct first)
• Severe renal impairment (CrCl <30-35 mL/min for oral agents) 1

Anabolic therapy discontinuation:

• Never stop romosozumab or teriparatide without immediately transitioning to bisphosphonate - this causes rapid bone loss and rebound fracture risk 2, 1

Denosumab discontinuation:

• Must transition to bisphosphonate when stopping to prevent severe rebound bone loss and vertebral fractures 1

Monitoring

• Repeat DXA: Every 1-2 years initially to assess treatment response
• Biochemical markers: Consider baseline and follow-up bone turnover markers
• Fracture surveillance: Assess for new vertebral fractures clinically (height loss, kyphosis, back pain)

Special Consideration for This Age Group

At 65 years old, she falls into the standard screening age where most guidelines uniformly recommend evaluation. The 2023 ACP guideline specifically addresses postmenopausal women and provides the most recent evidence-based recommendations, though it focuses primarily on fracture prevention rather than just bone density 2. The AACE/ACE 2020 guidelines provide more granular treatment selection guidance, emphasizing that four agents (alendronate, risedronate, zoledronate, denosumab) have the strongest evidence for broad-spectrum fracture reduction 1.

The key decision point is determining fracture risk category - standard oral bisphosphonates work excellently for most 65-year-old women with osteoporosis, reserving more expensive anabolic agents for those with very high fracture risk features.